Key Points
- CMO Joanne Donovan sold 50,000 shares at an average price of $38.57 for about $1.93 million, leaving her with 4,367 shares — a 91.97% reduction in her position.
- EWTX trades near $38 (one‑year range $12.15–$39.96) with a market cap of roughly $4.09 billion; analysts hold a consensus "Moderate Buy" with an average target of $38.13 despite a recent quarterly EPS miss and an expected -2.16 EPS for the year.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $31.29, for a total transaction of $163,646.70. Following the sale, the chief marketing officer owned 4,367 shares in the company, valued at approximately $136,643.43. This trade represents a 54.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Edgewise Therapeutics Stock Up 20.9%
Shares of NASDAQ EWTX opened at $38.01 on Wednesday. The firm's 50-day moving average price is $31.28 and its two-hundred day moving average price is $26.52. Edgewise Therapeutics, Inc. has a 52-week low of $12.15 and a 52-week high of $39.96. The stock has a market capitalization of $4.09 billion, a P/E ratio of -23.32 and a beta of 0.25.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, equities research analysts expect that Edgewise Therapeutics, Inc. will post -2.16 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have weighed in on EWTX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Edgewise Therapeutics in a research report on Monday, April 20th. Evercore reissued an "outperform" rating and set a $45.00 price target on shares of Edgewise Therapeutics in a report on Thursday, February 26th. Piper Sandler restated an "overweight" rating on shares of Edgewise Therapeutics in a research report on Monday, February 9th. HC Wainwright raised shares of Edgewise Therapeutics to a "strong-buy" rating in a report on Thursday, February 26th. Finally, Wedbush reiterated an "outperform" rating and issued a $32.00 price objective on shares of Edgewise Therapeutics in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.13.
Read Our Latest Analysis on Edgewise Therapeutics
Institutional Trading of Edgewise Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new position in Edgewise Therapeutics during the 4th quarter worth $50,000. Jones Financial Companies Lllp acquired a new position in shares of Edgewise Therapeutics during the first quarter valued at $47,000. Bessemer Group Inc. increased its holdings in shares of Edgewise Therapeutics by 1,170.3% during the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock valued at $38,000 after purchasing an additional 2,165 shares during the period. Steward Partners Investment Advisory LLC raised its stake in shares of Edgewise Therapeutics by 23.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company's stock valued at $71,000 after purchasing an additional 550 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in Edgewise Therapeutics in the second quarter worth about $45,000.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.
At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
